Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.57 |
| ▸ | CDK9 | P50750 | 11/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.57 |
| ▸ | CDK1 | P06493 | 7/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.54 |
| ▸ | FLT3 | P36888 | 4/20 | 0.54 |
| ▸ | CDK7 | P50613 | 5/20 | 0.53 |
| ▸ | CCNH | P51946 | 4/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.53 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086561 | 1.00 | CDK2 (0.57) | CDK2CDK9CCNT1CCNA2CDK1 | |
| SCHEMBL23906671 | 0.91 | CDK2 (0.56) | CDK2CDK9CDK1CCNB1FLT3 | |
| SCHEMBL30086876 | 0.91 | CDK2 (0.56) | CDK2CDK9CDK1CCNB1FLT3 | |
| SCHEMBL30086477 | 0.88 | JAK2 (0.61) | CDK2CDK9CCNT1CCNA2CDK1 | |
| SCHEMBL23906595 | 0.88 | JAK2 (0.61) | CDK2CDK9CCNT1CCNA2CDK1 | |
| SCHEMBL25263571 | 0.85 | CAMK2D (0.53) | CDK2CDK9CCNT1CCNA2CDK1 | |
| SCHEMBL30086420 | 0.85 | CAMK2D (0.53) | CDK2CDK9CCNT1CCNA2CDK1 | |
| SCHEMBL23906667 | 0.81 | CCNT1 (0.51) | CDK2CDK9CCNT1CCNA2CDK1 | |
| SCHEMBL30086644 | 0.81 | CCNT1 (0.51) | CDK2CDK9CCNT1CCNA2CDK1 | |
| SCHEMBL23906836 | 0.81 | IKBKB (0.48) | CDK2CDK9CDK1FLT3CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2021203131-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | CDK2 258/4885CDK9 654/4885CCNT1 3623/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | CDK2 258/4885CDK9 654/4885CCNT1 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.